Cargando…
HDAC1,2 inhibition impairs EZH2- and BBAP- mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma
Gain-of-function mutations in the catalytic site of EZH2 (Enhancer of Zeste Homologue 2), is observed in about 22% of diffuse large B-cell lymphoma (DLBCL) cases. Here we show that selective inhibition of histone deacetylase 1,2 (HDAC1,2) activity using a small molecule inhibitor causes cytotoxic or...
Autores principales: | Johnson, Danielle P., Spitz, Gabriella S., Tharkar, Shweta, Quayle, Steven N., Shearstone, Jeffrey R., Jones, Simon, McDowell, Maria E., Wellman, Hannah, Tyler, Jessica K., Cairns, Bradley R., Chandrasekharan, Mahesh B., Bhaskara, Srividya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467121/ https://www.ncbi.nlm.nih.gov/pubmed/25605023 |
Ejemplares similares
-
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer
por: Li, Xin, et al.
Publicado: (2021) -
The role of EZH1 and EZH2 in development and cancer
por: Lee, Soo Hyun, et al.
Publicado: (2022) -
Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
por: Coulter, Jonathan B., et al.
Publicado: (2023) -
Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer
por: Ma, Linlin, et al.
Publicado: (2019) -
Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer
por: Kim, Woojin, et al.
Publicado: (2013)